At OneChain, we believe in the transformative potential of CAR T therapies and work to take this technology a step further. By identifying novel, previously unexplored antigens, selecting those that are highly specific to tumour cells to minimise toxicity, and developing dual-targeting strategies that broaden patient eligibility and help prevent relapse, we aim to ensure that more patients can benefit from this technology.
Expanding access with off-the-shelf cell therapies
An allogeneic platform to make CAR T treatment cheaper, faster and universal
At OneChain, we’re developing an allogeneic CAR T platform based on γδ T cells, a unique population of immune cells with strong antitumour activity and low risk of immune-related complications. Easily expandable from stem cells and suitable for use across multiple patients, they offer a promising solution to the limitations of current autologous therapies for both haematological malignancies and solid tumours.